BCM
VRTX icon

Bienville Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bienville Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,000
Closed -$713K – 91
2014
Q4 		$713K Buy
+6,000
New +$676K 0.59% 29

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bienville Capital Management's VRTX Position: Q1 2015 in Review

Bienville Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2015, closing a stake of 6,000 shares — an estimated $713K sold.

Bienville Capital Management first reported a position in VRTX in Q4 2014 and held it in 1 quarter. The position peaked at $713K in Q4 2014. 479 funds tracked by Wall St. Rank hold VRTX as of Q1 2015.

  • Bienville Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Bienville Capital Management sold 6,000 Vertex Pharmaceuticals shares in Q1 2015, an estimated $713K.
  • Bienville Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Bienville Capital Management's Vertex Pharmaceuticals position peaked at $713K in Q4 2014.
  • 479 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2015.

Based on Bienville Capital Management's 13F filing for Q1 2015, filed 13 May 2015.